1st August 2020
Olaparib is the first in a new type of targeted cancer drug called a PARP inhibitor. The drug was developed thanks to pioneering research made possible by people just like you. Olaparib has so far been used to treat over 30,000 people with cancer worldwide – and many clinical trials are ongoing to see if olaparib can save the lives of more people with cancer.
In the mid-90s, Professor Steve Jackson came to Worldwide Cancer Research for funding for a research project. At the time, Professor Jackson did not imagine a drug like olaparib would be the end goal of his research. He wanted to learn more about the basics of cancer to open new avenues of research that might one day benefit people. The key discoveries he made with this research led him to develop the drug we know today as olaparib.
After many years of research and clinical trials, olaparib is now helping people with cancer live longer and, in some cases, has even cured patients – people like Sandy who took part in a clinical trial for olaparib and eventually became cancer-free.Sandy's story
PARP inhibitors, such as olaparib, are drugs that target a specific fault in cancer cells. The drug works by blocking a protein in cancer cells called PARP. The PARP protein is one of many proteins that exist in cells to help them repair damage to their DNA.
Daily life puts a strain on our DNA. UV radiation, polluted air and the day to day processes going on in our cells continuously batter our DNA. During these events, errors called DNA mutations can happen. If the damage is too great, the cell dies to protect the cells around it. If the errors are small, the cell uses a molecular repair kit, patches up the damaged DNA and continues as normal.
Two of the main tools a cell has in its repair kit are genes called PARP and BRCA. You might have heard of BRCA (the media dubbed it the "Angelina Jolie gene") because of its association with breast and ovarian cancer. BRCA can be damaged in cancer cells, meaning that they heavily rely on PARP to fix any DNA damage that occurs.
Olaparib, a PARP inhibitor, can stop PARP from repairing faults in these cancer cells. This leaves them with no tools to fix their DNA damage. Damage then accumulates over time until it’s bad enough to cause the cancer cells to die.
Olaparib has so far been used to treat 30,000 people worldwide.
In the UK, olaparib is currently approved for the treatment of certain types of ovarian cancer and reviews are underway to get olaparib approved for breast, prostate and pancreatic cancer.
In the US and the EU, olaparib is already approved for specific types of ovarian, breast, pancreatic and prostate cancer.
Our research projects wouldn't be possible without the funds we receive from people like you. Just £24 can pay for an hour of research.Support Us